Ritlecitinib vs Baricitinib for Alopecia Areata: 2025 Network Meta-Analysis Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in PMC open access, 2025
Ritlecitinib vs Baricitinib for Alopecia Areata: 2025 Network Meta-Analysis Research Summary
Study conclusion
This network meta-analysis and indirect treatment comparison found no significant difference in efficacy between ritlecitinib 50mg and baricitinib 4mg at 24 weeks for severe alopecia areata. Both are approved JAK inhibitors for this condition. Note: JAK inhibitors treat alopecia areata (immune-related patchy hair loss) — NOT androgenetic alopecia (pattern baldness).
Strength of evidence
Who it applies to
Who was studied
Adults with moderate-to-severe alopecia areata (immune-related patchy hair loss). Ritlecitinib 50mg vs baricitinib 4mg at week 24.
Who was NOT studied
People with androgenetic alopecia (pattern baldness). People with mild alopecia areata. Children.
What to look for when shopping
Ritlecitinib (Litfulo) and baricitinib (Olumiant) are both FDA-approved for severe alopecia areata. Both are prescription-only specialist medications. Neither is used for pattern baldness.
What research cannot help you decide
Which drug is better for your specific situation — both showed similar efficacy and the choice may depend on safety profile, cost, and individual response. This requires a specialist dermatologist.
Key findings
- No significant difference in efficacy between ritlecitinib 50mg and baricitinib 4mg at week 24 for severe alopecia areata
- Both drugs produced meaningful scalp hair regrowth
- These treatments are for alopecia areata only — NOT pattern baldness
- Both are FDA-approved for severe alopecia areata
- Comparison is indirect — no head-to-head direct RCT exists
What this study does not show
- 1.Whether one drug is better than the other for your specific situation — they showed similar efficacy.
- 2.Long-term comparative outcomes beyond 24 weeks.
- 3.Whether these drugs work for androgenetic alopecia (pattern baldness) — they do not.
Limitations
- 1.Indirect comparison — no direct head-to-head RCT exists.
- 2.Evidence applies to alopecia areata only — not pattern baldness.
- 3.Network meta-analysis introduces uncertainty compared to direct trial evidence.
- 4.Long-term comparative data beyond 24 weeks is absent.
Used in these articles
Links added as fact-checks and articles citing this study are published.